obesity drug news today glp-1 september 2025 A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio Beyond GLP-1: the next wave
Description
Peak appetite suppression, the strongest reduction in hunger and food-related thinking, typically occurs around weeks 12 to 14 at therapeutic doses
Physiologically-based pharmacokinetic modeling of atorvastatin incorporating delayed gastric emptying and acid-to-lactone conversion
Most patients find that symptoms become manageable or resolve entirely by weeks 4 to 8 at a given dose
Gong N, Fan H, Ma AN, Xiao Q, Wang YX
Gorgojo-Martnez has the following financial relationships: advisor on scientific boards for Astra-Zeneca, Janssen Pharmaceuticals, Eli Lilly and Company, Merck Sharp & Dohme and Novo-Nordisk
